Phase I/II Trial of Ruxolitinib in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer

PURPOSE: Preclinical data demonstrate STAT3 as an important regular in HER2+ tumors, and disruption of the IL6-JAK2-STAT-S100A8/S100A9 signaling cascade reduces HER2+ cell viability. Ruxolitinib is an FDA approved inhibitor of JAK1 and JAK2. We performed a phase I/II trial investigating the safety a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kearney, Matthew, Franks, Lauren, Lee, Shing, Tiersten, Amy, Makower, Della F, Cigler, Tessa, Mundi, Prabhjot, Chi, Dow-Chung, Goel, Anupama, Klein, Pam, Andreopoulou, Eleni, Sparano, Joseph, Trivedi, Meghna, Accordino, Melissa, Califano, Andrea, Hershman, Dawn L, Silva, Jose, Kalinsky, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487317/
https://www.ncbi.nlm.nih.gov/pubmed/34169393
http://dx.doi.org/10.1007/s10549-021-06306-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487317/
https://www.ncbi.nlm.nih.gov/pubmed/34169393
http://dx.doi.org/10.1007/s10549-021-06306-4

Ejemplares similares